Tech Company Financing Transactions

Principia Biopharma Funding Round

On 4/22/2014, Principia Biopharma raised $50 million in Series B financing from Sofinnova Ventures, Mission Bay Capital and Morgenthaler Ventures.

Transaction Overview

Company Name
Principia Biopharma
Announced On
4/22/2014
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series B
Investors

Sofinnova Ventures (Lead Investor) (Srinivas Akkaraju)

Mission Bay Capital

Morgenthaler Ventures (Nassim Usman)

New Leaf Venture Partners (Michael Dybbs)

OrbiMed (Peter Thompson)

SR One Capital Management (Simeon George)

Proceeds Purpose
The proceeds from this financing will be used to further advance the company's pipeline, including an oral BTK inhibitor for potential use in autoimmune disease and oncology, an oral, selective, irreversible FGFR inhibitor program for the treatment of solid tumors, an oral IL-17 pathway inhibitor program with utility across a range of autoimmune and inflammatory diseases as well as helping Principia expand into a clinical stage company.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
400 East Jamie Ct. 302
South San Francisco, CA 94080
USA
Phone
(650) 416-7700
Website
www.principiabio.com
Email Address
[email protected]
Overview
Principia is committed to changing the drug development paradigm. The company's reversible covalent technology platform rapidly and reliably produces compounds with superior selectivity, enabling development of multiple product candidates with substantial commercial potential.
Profile
Principia Biopharma LinkedIn Company Profile
Social Media
Principia Biopharma Company Twitter Account
Company News
Principia Biopharma News
Facebook
Principia Biopharma on Facebook
YouTube
Principia Biopharma on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Martin Babler
  Martin Babler LinkedIn Profile  Martin Babler Twitter Account  Martin Babler News  Martin Babler on Facebook
Chief Financial Officer
Christopher Chai
  Christopher Chai LinkedIn Profile  Christopher Chai Twitter Account  Christopher Chai News  Christopher Chai on Facebook
Chief Medical Officer
Steve Gourlay
  Steve Gourlay LinkedIn Profile  Steve Gourlay Twitter Account  Steve Gourlay News  Steve Gourlay on Facebook
Chief Scientific Officer
Jens Funk
  Jens Funk LinkedIn Profile  Jens Funk Twitter Account  Jens Funk News  Jens Funk on Facebook
Vice President
Ken Brameld
  Ken Brameld LinkedIn Profile  Ken Brameld Twitter Account  Ken Brameld News  Ken Brameld on Facebook
VP - Bus. Development
Roy Hardiman
  Roy Hardiman LinkedIn Profile  Roy Hardiman Twitter Account  Roy Hardiman News  Roy Hardiman on Facebook
VP - Human Resources
Betsy Santos
  Betsy Santos LinkedIn Profile  Betsy Santos Twitter Account  Betsy Santos News  Betsy Santos on Facebook
VP - Operations
Ann Neale
  Ann Neale LinkedIn Profile  Ann Neale Twitter Account  Ann Neale News  Ann Neale on Facebook
VP - Operations
Stefani Wolff
  Stefani Wolff LinkedIn Profile  Stefani Wolff Twitter Account  Stefani Wolff News  Stefani Wolff on Facebook

 

 

Browse more venture capital transactions:

Prev: 4/22/2014: Tubular Labs venture capital transaction
Next: 4/22/2014: Damballa venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.